The third article in our series about therapeutic monoclonal antibodies focuses on structural characterization and comparability analysis of biosimilars. We discuss existing evidence that shows that NMR spectroscopy is far superior to other established methods for comparability assessment, like FTIR, UV and circular dichroism (CD) spectroscopy, and differential scanning calorimetry (DSC).
The second part of our article series on antibody therapeutics discusses the field of biosimilar therapeutics, biosimilars, and the need for higher order structure (HOS) comparability analysis.
The development of new drugs of biological origin, the majority of which are monoclonal antibodies, is a major focus of modern-day drug design. The information on monoclonal antibody three-dimensional structure, in combination with antibody engineering, plays a central role in this process and has opened the way for the rapidly growing field of monoclöonal antibody therapeutics.
We're sharing here the latest company updates. They include a new publication, information about Lund Spring Symposium, and our expected move to new facilities at a new building at Medicon Village.